4.8 Article

Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma

期刊

CELL REPORTS
卷 42, 期 6, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.celrep.2023.112570

关键词

-

向作者/读者索取更多资源

The combination of BRAF and MEK inhibitors has shown promise in treating BRAF-mutant melanoma, but drug-tolerant persister cells limit treatment efficacy. RTK activation plays a key role in ERK reactivation and persister development.
The combination of BRAF and MEK inhibitors (BRAFi/MEKi) has shown promising response rates in treating BRAF-mutant melanoma by inhibiting ERK activation. However, treatment efficacy is limited by the emer-gence of drug-tolerant persister cells (persisters). Here, we show that the magnitude and duration of receptor tyrosine kinase (RTK) activation determine ERK reactivation and persister development. Our single-cell anal-ysis reveals that only a small subset of melanoma cells exhibits effective RTK and ERK activation and de-velops persisters, despite uniform external stimuli. The kinetics of RTK activation directly influence ERK signaling dynamics and persister development. These initially rare persisters form major resistant clones through effective RTK-mediated ERK activation. Consequently, limiting RTK signaling suppresses ERK acti-vation and cell proliferation in drug-resistant cells. Our findings provide non-genetic mechanistic insights into the role of heterogeneity in RTK activation kinetics in ERK reactivation and BRAFi/MEKi resistance, suggest-ing potential strategies for overcoming drug resistance in BRAF-mutant melanoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据